FOLH1 and prostate carcinoma: Ongoing trials are also investigating the use of novel RLTs in progressive mCRPC, including treatments using 177Lu linked to different PSMA-binding or other prostate cancer-specific ligands as well as treatments using different radionuclides, such as actinium-225, iodine-131, and lead-212 [11].